{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:52:06Z","timestamp":1791409926894,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110274","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:18:17Z","timestamp":1785453497000},"page":"110274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rational design, synthesis, and biological evaluation of novel PARP1 degraders for colon cancer therapy"],"prefix":"10.1016","volume":"181","author":[{"given":"Yang","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110274_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118202","article-title":"Recent advances in the synthesis of poly (ADP-ribose)","volume":"125","author":"Wu","year":"2025","journal-title":"Bioorg. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110274_bb0010","doi-asserted-by":"crossref","first-page":"19846","DOI":"10.1021\/acs.jmedchem.5c01335","article-title":"PARP7: an emerging therapeutic target-insights into biological functions and advances in small-molecule inhibitor development","volume":"68","author":"Qiu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110274_bb0015","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.32604\/biocell.2025.061725","article-title":"The crucial role of NAD+ in mitochondrial metabolic regulation","volume":"49","author":"Mishra","year":"2025","journal-title":"Biocell"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110274_bb0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/BST20241633","article-title":"\u2018Where is my gap\u2019: mechanisms underpinning PARP inhibitor sensitivity in cancer","volume":"53","author":"Buckley-Benbow","year":"2025","journal-title":"Biochem. Soc. Trans."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110274_bb0025","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1021\/acs.chemrev.2c00851","article-title":"Regulation of biomolecular condensates by poly(ADP-ribose)","volume":"123","author":"Rhine","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.110274_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2026.101214","article-title":"The complex landscape of non-coding RNAs in olaparib response and resistance","volume":"47","author":"Tahamipour","year":"2026","journal-title":"Cancer Treatment Res. Commun."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110274_bb0035","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110274_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118719","article-title":"DNA repair pathways in ovarian cancer: implications for therapy and resistance","volume":"193","author":"Miras","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110274_bb0045","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.molcel.2026.02.018","article-title":"Replicative gaps in DNA damage tolerance, genome instability, and cancer therapy","volume":"86","author":"Falbo","year":"2026","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.110274_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117347","article-title":"Research progress in DNA damage response (DDR)-targeting modulators: from hits to clinical candidates","volume":"287","author":"Cheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110274_bb0055","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1021\/acs.chemrestox.6c00176","article-title":"The expanding landscape of ADP-Ribosylation: protein, DNA, RNA, and mitochondrial regulation","volume":"39","author":"Sin","year":"2026","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bioorg.2026.110274_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108058","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer","volume":"222","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110274_bb0065","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.1021\/acs.jmedchem.4c00113","article-title":"New horizons of synthetic lethality in Cancer: current development and future perspectives","volume":"67","author":"Previtali","year":"2024","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110274_bb0070","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1021\/acs.jmedchem.5c03804","article-title":"Design and synthesis of USP1 inhibitors: synergistic antitumor activity with PARP inhibitors in triple-negative breast Cancer","volume":"69","author":"Teng","year":"2026","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110274_bb0075","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1021\/acsmedchemlett.5c00530","article-title":"Development of novel compounds and methods for treatment of PARPs mediated disease","volume":"16","author":"Zhou","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110274_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178298","article-title":"PARPs in tumor immunology: signal transduction and combination therapy for the future","volume":"1007","author":"Jiang","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110274_bb0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejmech.2019.01.024","article-title":"Medicinal chemistry approaches of poly ADP-ribose polymerase 1 (PARP1) inhibitors as anticancer agents - a recent update","volume":"165","author":"Jain","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110274_bb0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ijgc-2022-003698","article-title":"Overcoming PARP inhibitor resistance in ovarian cancer","volume":"33","author":"Soberanis Pina","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110274_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115709","article-title":"Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities","volume":"259","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2026.102757","article-title":"PARP inhibitors target cellular energy metabolism: mechanisms of action and clinical implications","volume":"68","author":"Li","year":"2026","journal-title":"Transl. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110274_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189221","article-title":"Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer","volume":"1879","author":"Bi","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA) - Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110274_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118779","article-title":"Medicinal chemistry strategies targeting viral proteases: from classical design to next-generation therapeutics","volume":"310","author":"Alturki","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114321","article-title":"Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer","volume":"236","author":"Pu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117212","article-title":"Recent advances in developing targeted protein degraders","volume":"284","author":"Cheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114533","article-title":"Recent advances in the development of EGFR degraders: PROTACs and LYTACs","volume":"239","author":"Hong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110274_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104601","article-title":"LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects","volume":"31","author":"Niebel","year":"2026","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.110274_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108491","article-title":"Proteolysis targeting chimera, molecular glue degrader and hydrophobic tag tethering degrader for targeted protein degradation: mechanisms, strategies and application","volume":"161","author":"Pan","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110274_bb0145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.110274_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112539","article-title":"PROTAC: a promising technology for cancer treatment","volume":"203","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116725","article-title":"PROTAC technology: from drug development to probe technology for target deconvolution","volume":"276","author":"Yan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114290","article-title":"The state of the art of PROTAC technologies for drug discovery","volume":"235","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115037","article-title":"PROTACS: a technology with a gold rush-like atmosphere","volume":"247","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110274_bb0170","doi-asserted-by":"crossref","first-page":"10183","DOI":"10.1021\/acs.jmedchem.2c00691","article-title":"Targeting Undruggable transcription factors with PROTACs: advances and perspectives","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115793","article-title":"Current advances and development strategies of orally bioavailable PROTACs","volume":"261","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110274_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2025.100295","article-title":"Hydrophobic tagging: a promising paradigm for targeted protein degradation","volume":"5","author":"Xin","year":"2026","journal-title":"Cell Insight"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110274_bb0185","doi-asserted-by":"crossref","first-page":"10917","DOI":"10.1021\/acs.jmedchem.3c00736","article-title":"Small-molecule hydrophobic tagging: a promising strategy of Druglike Technology for Targeted Protein Degradation","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110274_bb0190","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nchembio.597","article-title":"Small-molecule hydrophobic tagging\u2013induced degradation of HaloTag fusion proteins","volume":"7","author":"Neklesa","year":"2011","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110274_bb0195","first-page":"392","article-title":"HaloTag: a novel reporter gene for positron emission tomography","volume":"3","author":"Hong","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bioorg.2026.110274_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118269","article-title":"Design, synthesis, and biological evaluation of ML162-based glutathione peroxidase 4 (GPX4) degraders with hydrophobic tags","volume":"301","author":"Ning","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115741","article-title":"Hydrophobic tag-based protein degradation: development, opportunity and challenge","volume":"260","author":"He","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110274_bb0210","doi-asserted-by":"crossref","first-page":"8791","DOI":"10.1021\/acs.jmedchem.4c00131","article-title":"Novel acyl Thiourea-based hydrophobic tagging degraders exert potent anti-influenza activity through two distinct endonuclease polymerase acidic-targeted degradation pathways","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2026.110274_bb0215","doi-asserted-by":"crossref","first-page":"21344","DOI":"10.1021\/acs.jmedchem.4c02273","article-title":"Development of novel silicon-based hydrophobic tags (SiHyT) for targeted proteins degradation","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0220","doi-asserted-by":"crossref","DOI":"10.2991\/978-94-6463-932-2","article-title":"Selective degradation of DAPK1 via a novel hydrophobic tagging attenuates tau pathology in Alzheimer\u2019s disease","author":"Li","year":"2025","journal-title":"J. Adv. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110274_bb0225","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1021\/acs.jmedchem.4c02269","article-title":"Discovery of D-ring-contracted artemisinin as a potent hydrophobic tag for targeted protein degradation","volume":"68","author":"Qing","year":"2025","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110274_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.109192","article-title":"Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: past, present and future perspectives","volume":"35","author":"Ha","year":"2024","journal-title":"Chin. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110274_bb0235","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.apsb.2025.04.023","article-title":"Innovative discovery and mechanistic validation of HyT-PD ligands for selective CDK9-targeted protein degradation","volume":"15","author":"Zhai","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.110274_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118121","article-title":"Targeted degradation of Werner syndrome helicase (WRN) via ligand-directed covalent hydrophobic tagging","volume":"300","author":"Tao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110274_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115819","article-title":"Bridged PROTAC, DNA-based PROTAC and hydrophobic tag technologies for targeted protein degradation","volume":"232","author":"Gao","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110274_bb0250","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.chembiol.2012.04.008","article-title":"Inhibitor mediated protein degradation","volume":"19","author":"Long","year":"2012","journal-title":"Chem. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110274_bb0255","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110274_bb0260","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1021\/acs.jmedchem.2c00257","article-title":"Discovery of small-molecule degraders of the CDK9-cyclin T1 complex for targeting transcriptional addiction in prostate Cancer","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:17:57Z","timestamp":1791407877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":52,"alternative-id":["S0045206826008102"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110274","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design, synthesis, and biological evaluation of novel PARP1 degraders for colon cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110274"}}